Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD: A cost-effectiveness analysis for Germany;Roflumilast in Kombination mit langwirksamen Bronchodilatatoren in der Versorgung von Patienten mit schwerer und sehr schwerer COPD: Eine Kosten-Effektivitäts-Analyse für Deutschland

Deutsche Medizinische Wochenschrift

Volumn 138, Issue 4, 2013, Pages 119-125

  Nowak, D ^a   Ehlken, B ^b   Kotchie, R ^b   Wecht, S ^c   Magnussen, H ^d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b IQVIA   (United States)

^c Nycomed GmbH   (Germany)

^d Pneumologisches Forschungsinstitut Am Krankenhaus Grohansdorf   (Germany)

Author keywords

bronchodilator; COPD; cost effectiveness; roflumilast

Indexed keywords

BRONCHODILATING AGENT; ROFLUMILAST; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; GERMANY; HUMAN; LIFE EXPECTANCY; MARKOV CHAIN; QUALITY OF LIFE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; FEMALE; HEALTH CARE COST; MALE; MIDDLE AGED; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; STATISTICS; TREATMENT OUTCOME;

AMINOPYRIDINES; BENZAMIDES; BRONCHODILATOR AGENTS; COST-BENEFIT ANALYSIS; CYCLOPROPANES; DRUG COMBINATIONS; FEMALE; GERMANY; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 4 INHIBITORS; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84872186395     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0032-1327416     Document Type: Article

References (39)

1. Abholz H. H., Gillissen A., Magnussen H. et al. Nationale VersorgungsLeitlinien - COPD - Langfassung 2011. http://www.versorgungsleitlinien.de/themen/copd/nvl-copd (Zugang: November 2011)
2. Bateman E. D., Rabe K. F., Calverley P. MA et al. Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history. Eur Respir J: 2011; 38 553 560
3. Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respir Med: 2003; 97 (Suppl C): S71 S79
4. Calverley P. M., Rabe K. F., Goehring U. M. et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet: 2009; 374 685 694
5. Chuck A., Jacobs P., Mayers I. et al. Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease. Can Respir J: 2008; 15 437 443
6. DAXAS® Summary of Product Characteristics (SmPC) September 2010
7. Engstrom A. The cost-effectiveness of Roflumilast in Treating COPD in Sweden. ISPOR 14th Annual European Congress, Madrid, Spain 5-8 November: 2011; Poster No. PRS39
8. EMA DAXAS: Zusammenfassung des EPAR für die Öffentlichkeit. http://www.ema.europa.eu/docs/de-DE/document-library/EPAR--Summary-for-the-public/human/001179/WC500095211.pdf (Zugang: November 2011)
9. Fabbri L. M., Calverley P. M., Izquierdo-Alonso J. L. et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet: 2009; 374 695 703
10. Geldmacher H., Biller H., Herbst A. et al. Die Prävalenz der chronisch obstruktiven Lungenerkrankung (COPD) in Deutschland. Ergebnisse der BOLD-Studie. Dtsch Med Wochenschr: 2008; 133 50 2609 2614
11. Gesundheitsberichterstattung des Bundes. Sterbefälle - Todesursachenstatistik COPD (ICD-10 J44): 2008; www.gbe-bund.de (Zugang: Juli 2010)
12. Gesundheitsberichterstattung des Bundes. Diagnosedaten der Krankenhäuser: 2008; www.gbe-bund.de (Zugang: November 2010)
13. GOLD Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease - revised 2011. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html (Zugang: Januar 2011)
14. GOLD Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease Updated 2009. http://www.goldcopd.org/Guidelines/guidelines-resources.html (Zugang: November 2009)
15. Grootendorst D. C., Gauw S. A., Verhoosel R. M. et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax: 2007; 62 1081 1807
16. Heinen-Kammerer T., Daniel D., Stratmann L. et al. Kosteneffektivität der Psoriasis-Behandlung mit Etanercept in Deutschland. J Dtsch Dermatol Ges: 2007; 5 762 568
17. Hertel N., Kotchie R. W., Samyshkin Y. et al. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis: 2012; 7 183 199
18. Hoogendoorn M., Al M., Beeh K. M. et al. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. Eur Respir J: 2012; Jun 14. [Epub ahead of print]
19. Hurst J. R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med: 2011; 363 1128 1138
20. InEK GmbH - Institut für das Entgeltsystem im Krankenhaus G-DRG V2008/2010 Report-Browser.: 2010
21. Kardos P., Wencker M., Glaab T. et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med: 2007; 175 144 149
22. Rote Liste Service GmbH Rote Liste 2010 - Arzneimittelverzeichnis für Deutschland (einschlieβlich EU-Zulassungen und bestimmter Medizinprodukte). Frankfurt/Main
23. Menn P., Heinrich J., Huber J. et al. Direct medical costs of COPD - an excess cost approach based on two population-based studies. Respiratory Medicine: 2012; 106 540 548
24. Royal College of Physicians of London, British Thoracic Society and British Lung Foundation Report of The National Chronic Obstructive Pulmonary Disease Audit 2008: clinical audit of COPD exacerbations admitted to acute NHS units across the UK. http://www.rcplondon.ac.uk/sites/default/files/report-of-the-national-copd-audit-2008-clinical-audit-of-copd-exacerbations-admitted-to-acute-nhs-units-across-the-uk.pdf (Zugang: 9.1.2013)
25. Nielsen R., Johannessen A., Benediktsdottir B. et al. Present and future costs of COPD in Iceland and Norway: results from the BOLD study. Eur Respir J: 2009; 34 850 857
26. Nowak D., Dietrich E. S., Oberender P. et al. Krankheitskosten von COPD in Deutschland. Pneumologie: 2004; 58 837 844
27. Rabe K. F., Hurd S., Anzueto A. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med: 2007; 176 532 555
28. Rutten-van Molken M. P., Hoogendoorn M., Lamers L. M. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics: 2009; 27 465 477
29. Samyshkin Y., Radford M., Schlunegger M. P., Gooss A. Cost-effectiveness of roflumilast as an ad-on to bronchodilator and to combination of bronchodilator with anti-inflammatory therapies in patients with severe and very severe COPD and a history of exacerbations in Switzerland. ISPOR 14th Annual European Congress, Madrid, Spain 5-8 November: 2011; Poster No. PRS39 http://www.ispor.org/research-study-digest/details.asp
30. Schwander B., Gradl B., Zollner Y. et al. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe - the HEALTH model. Value Health: 2009; 12 857 871
31. Seemungal T. A., Donaldson G. C., Bhowmik A. et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med: 2000; 161 1608 1613
32. Schulenburg Graf von der J. M., Greiner W., Jost F. et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health: 2008; 11 539 544
33. Soler-Cataluna J. J., Martinez-Garcia M. A., Roman Sanchez P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax: 2005; 60 925 931
34. Statistisches Bundesamt Deutschland Aktuelle Sterbetafeln für Deutschland 2006/08. http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/DE/Navigation/Statistiken/Bevoelkerung/GeburtenSterbefaelle/Tabellen.psml (Zugang: 15 Juli 2010)
35. Steer J., Gibson G. J., Bourke S. C. Predicting outcomes following hospitalization for acute exacerbations of COPD. QJM: 2010; 103 817 829
36. Sun S. X., Marynchenko M., Banerjee R. et al. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. J Med Econ: 2011; 14 805 815
37. Towse A., Pritchard C. Does NICE have a threshold? An external view. In: Towse A., Pritchrad C., Devlin N. editors. Cost-Effectiveness Thresholds. Economic and Ethical Issues. London King's Fund and Office of Health Economics: 2002
38. Vogelmeier C., Buhl R., Criee C. P. et al. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie: 2007; 61 e1 40
39. Wedzicha J. A., Seemungal T. A. COPD exacerbations: defining their cause and prevention. Lancet: 2007; 370 786 796